Reflux medications linked to chronic kidney disease and kidney failure

A recent analysis has linked certain medications commonly used to treat heartburn, acid reflux, and ulcers with the development of kidney disease. The findings will be presented at ASN Kidney Week 2017 October 31-November 5 at the Ernest N. Morial Convention Center in New Orleans, LA.

Proton pump inhibitors (PPIs), which reduce gastric acid production, are one of the most commonly prescribed medications worldwide. Recent studies have raised concerns over a potential increased risk of kidney problems among PPIs users but the results of those studies were inconsistent.

To investigate, Charat Thongprayoon, MD (Bassett Medical Center), and his colleagues conducted an analysis of published studies that reported the risk of chronic kidney disease or kidney failure among PPI users compared with non-users.

Five studies with 536,902 participants met the eligibility criteria and were included in the meta-analysis. Individuals who used PPIs had a 33% increased relative risk of CKD or kidney failure when compared with non-users.

"This study demonstrates a significant association between the use of PPIs and increased risks of and ," said Dr. Thongprayoon. "Although no causal relationship has been proven, providers should consider whether PPI therapy is indicated for patients. Chronic use of PPIs should be avoided if not really indicated." 


Explore further

Acid reflux medications may increase kidney disease risk

More information: Study: "Proton Pump Inhibitors and Risk of Chronic Kidney Diseases: A Meta-Analysis" (Abstract 2763180)
Citation: Reflux medications linked to chronic kidney disease and kidney failure (2017, November 5) retrieved 18 July 2019 from https://medicalxpress.com/news/2017-11-reflux-medications-linked-chronic-kidney.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
5 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more